cost containment

 In 2013 the Global Drug Facility reduced the price of the second-line drugs it supplies for multidrug-resistant tuberculosis (MDR TB): the overall cost of the longest and most expensive treatment regimen for a patient decreased by 26%, from US$7,890 in 2011 to US$5,822 in 2013. The price of treatment for MDR TB was reduced by consolidating orders to achieve large purchase volumes, by international, competitive bidding and by the existence of donor-funded medicine stockpiles. The rise in the number of suppliers of internationally quality-assured drugs was also important. The savings achieved from lower drug costs could be used to increase the number of patients on high-quality treatment.

Subscribe to RSS - cost containment